Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Cell replacement therapies
- Parkinson's disease
- Various symptoms of PD
- Pathology
- Symptomatic therapies
- Alternative: neural transplantation
- Dopamine cells for PD?
- How does it work?
- Early rodent studies
- Clinical trials: graft survival
- First PD clinical trials
- Summary of PD clinical trials
- Off L-dopa dyskinesia
- Dyskinesia in transplantation
- What do we do next?
- Nigral graft model (PD)
- Amphetamine-induced rotation
- Cognitive and motor deficits
- Stimulus-response learning
- Nigral grafts in the choice reaction time task
- Impact of dopamine to serotonin cell ratio
- Gold standard cell therapy
- Cell sources
- Which cells? (PD)
- Deriving DAergic cells from stem cells
- ES-derived dopaminergic neurons - in vitro
- ES-derived dopaminergic neurons - in vivo
- ES-derived neurons in different animal models
- Huntington's disease
- Genetics of HD
- Neuronal pathology in HD
- Motor deficits
- Psychiatric dysfunction
- Cognitive decline
- Why transplant in HD?
- Preclinical studies
- Striatal grafts in HD: Florida
- Striatal grafts in HD: Créteil (design)
- Striatal grafts in HD: Créteil (PET)
- Striatal grafts in HD: Barker et al., 2014
- Summary of clinical trials
- Outstanding Issues for transplantation
- Striatal graft model (HD)
- Mechanisms of action
- Skilled motor behaviour
- Learning to use the transplant
- Which cells? (HD)
- ES-derived medium spiny neurons (design)
- ES-derived medium spiny neurons (results)
- Summary
- Acknowledgments
Topics Covered
- Neural transplantation of primary fetal tissue and stem cells
- Parkinson’s and Huntington’s disease
- Dopaminergic and medium spiny neurons
- Results of clinical trials
- Pre-clinical testing in rodent models of disease
Talk Citation
Lelos, M.J. (2013, November 5). Primary and stem cell transplantation for functional repair of striatal degeneration in Parkinson’s and Huntington’s disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/UNRZ3517.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Mariah J. Lelos has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Primary and stem cell transplantation for functional repair of striatal degeneration in Parkinson’s and Huntington’s disease
A selection of talks on Neuroscience
Hide